Myogen GmbH

Rochusstrasse 175-177

53125 Bonn/Germany

Tel.: 0228-74879-0

Fax: 0228-74879-20

info@myogen.de

www.myogen.com 

www.perfan.com

<typohead type=2>Overview of Myogen</typohead>

Executive Summary Highlights Large Therapeutic Markets: Chronic Heart Failure (CHF) Proprietary Target Discovery and Validation Program Late Stage Product Pipeline Additional In-Licensing Opportunities Near-term Revenues Leading Scientific Collaborators and Exclusive Access to Human Heart Tissue Bank Experienced Management Team and Board

Myogen is a privately held Colorado-based biopharmaceutical company with a german based european subsidiary focused on the development of therapeutic drugs for the treatment of heart failure and related cardiovascular complications. The company was founded in 1996 around three strategic assets:

<typolist type="1">

A scientific/clinical team with a broad knowledge of the biochemistry and clinical treatment of heart muscle disease and the clinical syndrome of heart failure;
A discovery research program supported by a large, well characterized human heart tissue bank; and
A series of scientific discoveries that define the molecular mechanisms by which human myocardial failure occurs.

</typolist>

[zurück]